More data will be needed from AstraZeneca’s coronavirus vaccine trials to determine the drug’s safety and efficacy following concerns from experts in the U.S., scientists from the University of Oxford and the World Health Organization said on Friday.”There’s always a problem in announcing scientific results by press release, and that is that you don’t have all the data out there and people aren’t able to really look and think about the data properly,” Sir John Bell, the Regius professor of medicine at Oxford University, told CNBC’s “Closing Bell” on Friday.Shares of AstraZeneca dipped this week after the …
